The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
Authors:
- Ryoji TakadaRTRyoji Takada
- Kenji IkezawaKIKenji Ikezawa
- Kazuma DaikuKDKazuma Daiku
- Shingo MaedaSMShingo Maeda
- Yutaro AbeYAYutaro Abe
- Makiko UrabeMUMakiko Urabe
- Yugo KaiYKYugo Kai
- Takuo YamaiTYTakuo Yamai
- Nobuyasu FukutakeNFNobuyasu Fukutake
- Tasuku NakaboriTNTasuku Nakabori
- Hiroyuki UeharaHUHiroyuki Uehara
- Reiko AshidaRAReiko Ashida
Open Access
Abstract
An optimal therapeutic strategy for unresectable locally advanced pancreatic cancer (UR-LAPC) has not been established. This study investigated the therapeutic efficacy of chemoradiotherapy (CRT) following induction chemotherapy with gemcitabine plus nab-paclitaxel (GnP) (CRT group) compared with systemic chemotherapy alone (CTx group) in patients with UR-LAPC. This was a retrospective study of 63 consecutive patients with UR-LAPC treated at our department in a Japanese cancer referral center between February 2015 and July 2018. We excluded patients who underwent other regimens and those enrolled in another prospective study. The CRT group (n = 25) exhibited significantly better progression-free survival (PFS) and overall survival (OS) than the CTx group (n = 20, PFS 17.9 vs. 7.6 months, p = 0.044; OS 29.2 vs. 17.4 months, p < 0.001). In the multivariate analyses, CRT following induction chemotherapy was identified as an independent prognostic factor for OS. Seven (15.6%) patients underwent conversion surgery, all of whom were in the CRT group. The R0 resection rate was 85.7% (6/7). In summary, patients with UR-LAPC experienced favorable treatment outcomes after receiving GnP as the first-line chemotherapy, especially when receiving additional CRT. Thus, this treatment strategy represents a promising treatment option for selected patients with UR-LAPC.Keywords
This publication has 27 references indexed in Scilit:
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without ErlotinibJAMA, 2016
- Management of borderline and locally advanced pancreatic cancer: Where do we stand?World Journal of Gastroenterology, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Duodenal Toxicity After Fractionated Chemoradiation for Unresectable Pancreatic CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group TrialJournal of Clinical Oncology, 2011
- Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patientsExpert Review of Anticancer Therapy, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO studyAnnals of Oncology, 2008
- Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III StudiesJournal of Clinical Oncology, 2007